• Publications
  • Influence
Rivaroxaban versus warfarin in nonvalvular atrial fibrillation.
TLDR
In patients with atrial fibrillation, rivaroxaban was noninferior to warfarin for the prevention of stroke or systemic embolism and there was no significant between-group difference in the risk of major bleeding, although intracranial and fatal bleeding occurred less frequently in the rivroxaban group. Expand
Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke.
TLDR
As compared with placebo, intravenous alteplase administered between 3 and 4.5 hours after the onset of symptoms significantly improved clinical outcomes in patients with acute ischemic stroke; altePlase was more frequently associated with symptomatic intracranial hemorrhage. Expand
Updated European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist anticoagulants in patients with non-valvular atrial fibrillation.
TLDR
The current manuscript is an update of the original Practical Guide, published in June 2013, and listed 15 topics of concrete clinical scenarios for which practical answers were formulated, based on available evidence. Expand
Stent-retriever thrombectomy after intravenous t-PA vs. t-PA alone in stroke.
TLDR
In patients receiving intravenous t-PA for acute ischemic stroke, thrombectomy with the use of a stent retriever within 6 hours after onset improved functional outcomes at 90 days. Expand
Intravenous thrombolysis with recombinant tissue plasminogen activator for acute hemispheric stroke. The European Cooperative Acute Stroke Study (ECASS)
TLDR
Intravenous thrombolysis in acute ischemic stroke is effective in improving some functional measures and neurologic outcome in a defined subgroup of stroke patients with moderate to severe neurologic deficit and without extended infarct signs on the initial CT scan, however, the identification of this subgroup is difficult. Expand
Thrombolysis with alteplase for acute ischaemic stroke in the Safe Implementation of Thrombolysis in Stroke-Monitoring Study (SITS-MOST): an observational study
TLDR
These data confirm that intravenous alteplase is safe and effective in routine clinical use when used within 3 h of stroke onset, even by centres with little previous experience of thrombolytic therapy for acute stroke. Expand
European Heart Rhythm Association Practical Guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation.
TLDR
New oral anticoagulant drugs are an alternative for vitamin K antagonists to prevent stroke in patients with non-valvular atrial fibrillation (AF) and many unresolved questions on how to optimally use these drugs in specific clinical situations remain. Expand
Association of outcome with early stroke treatment: pooled analysis of ATLANTIS, ECASS, and NINDS rt-PA stroke trials
TLDR
The sooner that rt-PA is given to stroke patients, the greater the benefit, especially if started within 90 min, which suggests a potential benefit beyond 3 h, but this potential might come with some risks. Expand
Effect of treatment delay, age, and stroke severity on the effects of intravenous thrombolysis with alteplase for acute ischaemic stroke: a meta-analysis of individual patient data from randomised
TLDR
Alteplase increased the odds of a good stroke outcome, with earlier treatment associated with bigger proportional benefit, and Proportional treatment benefits were similar irrespective of age or stroke severity. Expand
Early decompressive surgery in malignant infarction of the middle cerebral artery: a pooled analysis of three randomised controlled trials
TLDR
In patients with malignant MCA infarction, decompressive surgery undertaken within 48 h of stroke onset reduces mortality and increases the number of patients with a favourable functional outcome. Expand
...
1
2
3
4
5
...